Specialty distribution and provider platforms drove September-quarter profit gains at the Big Three as brand pricing weighed on results.
|Articles|March 19, 2021
The verdict: Fujifilm to take its $2B CDMO investment to North Carolina
Cell culture facility expected to be largest in North America, according to the manufacturer
Advertisement
Fujifilm Corporation has selected Holly Springs, NC as the location for its new large-scale cell culture production site in the US. The
Fujifilm Diosynth Biotechnologies, a Fujifilm subsidiary with locations in the US, UK and Denmark, will be in charge of the new facility.
A thorough evaluation process was utilized in order to choose Holly Springs for the new location. The city was selected for its strong pool of technical talent, local resources and partners with the right competencies, clean energy resources, and sustainability for future growth. Fujifilm also owns a facility in nearby Morrisville, NC.
Advertisement
Related to this article
In this week's Pharma Pulse, Cencora agrees to acquire American Oncology Network, five major employers back electronic prior authorization for self-funded health plans and FDA finalizes its guidance on prescription drug apps and software.
Bob Cochran, former senior director, trade relations at Incyte, discusses direct-to-patient models, specialty launches and distribution strategy.
A CMS final rule codifies Medicare drug price negotiation from 2029, adds a fixed combination drug policy and implements a small biotech price floor.
Generative AI has made pharma teams faster, but real value depends on redesigning commercialization workflows, especially as agentic AI raises the governance stakes.
Siloed pricing, contracting and affordability decisions can undercut a launch. IQVIA experts explain how system-level modeling surfaces trade-offs early.
Nuvera’s PURE Engagement research, built on feedback from more than 2,300 physicians and support staff, ranks 2026 patient support leaders by company size and therapeutic area.
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
How CMS’ Final Negotiation Rule Treats New Drug Formulations
2
Bob Cochran: Direct-to-Patient Was a 'Watershed Moment' for Commercial Trade
3
The AI Efficiency Trap: Why Faster Tasks Alone Won’t Transform Life Sciences
4
Big Three Distributors Lean on Specialty for Profit Growth
5